[AKRX] Akorn, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 21.71 Change: 0.63 (2.99%)
Ext. hours: Change: 0 (0%)

chart AKRX

Refresh chart

Strongest Trends Summary For AKRX

AKRX is in the long-term up 276% in 24 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, vaccines, and others. The company operates in three segments: Ophthalmic, Hospital Drugs & Injectables, and Contract Services. The Ophthalmic segment markets diagnostic products, such as mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others for use in the office setting; therapeutic products, including antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; non-pharmaceutical products comprising artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers; and over-the-counter dry eye and

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS1.68 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 151.41% Sales Growth - Q/Q71.65% P/E19.93
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA1.85% ROE9.14% ROI
Current Ratio3.68 Quick Ratio2.71 Long Term Debt/Equity3.1 Debt Ratio0.35
Gross Margin50.18% Operating Margin16.31% Net Profit Margin5.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities972.31 M Cash From Investing Activities-966.54 M Cash From Operating Activities30.92 M Gross Profit128.38 M
Net Profit34.23 M Operating Profit71.91 M Total Assets1.91 B Total Current Assets494.33 M
Total Current Liabilities134.16 M Total Debt1.12 B Total Liabilities1.52 B Total Revenue227.83 M
Technical Data
High 52 week33.56 Low 52 week3.33 Last close3.64 Last change-5.94%
RSI48.76 Average true range0.32 Beta0.93 Volume2.35 M
Simple moving average 20 days-0.15% Simple moving average 50 days-30.37% Simple moving average 200 days-72.33%
Performance Data
Performance Week4.6% Performance Month-17.65% Performance Quart-41.85% Performance Half-74.07%
Performance Year-89.13% Performance Year-to-date7.37% Volatility daily5.48% Volatility weekly12.26%
Volatility monthly25.12% Volatility yearly87.01% Relative Volume219.78% Average Volume3.71 M
New High New Low

News

2019-08-14 15:30:05 | Is Akorn NASDAQ:AKRX A Risky Investment?

2019-08-05 16:15:04 | Edited Transcript of AKRX earnings conference call or presentation 1-Aug-19 1:00pm GMT

2019-08-02 07:24:08 | Akorn AKRX Q2 2019 Earnings Call Transcript

2019-08-01 08:55:12 | Akorn AKRX Reports Q2 Loss, Tops Revenue Estimates

2019-07-25 10:33:02 | Analysts Estimate Akorn AKRX to Report a Decline in Earnings: What to Look Out for

2019-07-11 16:32:15 | Akorn to Report Second Quarter 2019 Financial Results and Host Conference Call

2019-07-09 08:02:30 | See what the IHS Markit Score report has to say about Akorn Inc.

2019-06-28 07:00:00 | Akorn Announces Launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%

2019-06-27 11:20:30 | Did Hedge Funds Drop The Ball On Akorn, Inc. AKRX ?

2019-06-25 11:00:52 | Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues

2019-06-25 10:32:09 | Akorn gets FDA warning letter for another manufacturing plant

2019-06-25 09:41:21 | Akorn Files Complaint on Fresenius' Canceled Bid

2019-06-25 08:17:00 | Drugmaker Akorn Receives FDA Warning Letter Regarding N.J. Facility

2019-06-25 08:08:11 | UPDATE 3-Akorn gets FDA warning letter for another manufacturing plant

2019-06-25 07:44:00 | Generics maker Akorn receives warning letter from the FDA relating to NJ facility

2019-06-25 07:35:00 | Akorn Receives FDA Warning Letter

2019-06-14 07:01:32 | How Many Akorn, Inc. NASDAQ:AKRX Shares Did Insiders Buy, In The Last Year?

2019-06-10 08:03:20 | See what the IHS Markit Score report has to say about Akorn Inc.

2019-06-01 08:08:16 | See what the IHS Markit Score report has to say about Akorn Inc.

2019-05-30 08:04:09 | See what the IHS Markit Score report has to say about Akorn Inc.

2019-05-30 07:59:05 | Akorn to Present at the Jefferies 2019 Global Healthcare Conference

2019-05-21 09:02:54 | See what the IHS Markit Score report has to say about Akorn Inc.

2019-05-21 07:40:14 | The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

2019-05-20 16:05:00 | Akorn Receives FDA Approval for Azelastine Hydrochloride Nasal Spray, 0.1%

2019-05-20 08:01:33 | Akorn to Present at the RBC Capital Markets Healthcare Conference

2019-05-12 21:49:44 | Here’s What Hedge Funds Think About Akorn, Inc. AKRX

2019-05-08 09:24:51 | Akorn AKRX Q1 2019 Earnings Call Transcript

2019-05-07 17:00:59 | Edited Transcript of AKRX earnings conference call or presentation 7-May-19 2:00pm GMT

2019-05-07 08:35:12 | Akorn AKRX Reports Q1 Loss, Tops Revenue Estimates

2019-05-07 08:02:58 | See what the IHS Markit Score report has to say about Akorn Inc.

2019-05-07 07:24:26 | Akorn: 1Q Earnings Snapshot

2019-05-07 07:05:00 | Akorn Provides Preliminary First Quarter 2019 Results and Full Year Guidance

2019-04-24 09:14:21 | Introducing Akorn NASDAQ:AKRX, The Stock That Tanked 89%

2019-04-22 19:00:00 | Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period AKRX

2019-04-22 15:00:00 | FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

2019-04-22 14:27:13 | Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.

2019-04-22 12:58:02 | Here's Why Akorn Stock Rose as Much as 14.4% Today

2019-04-22 11:09:17 | DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-22 09:58:00 | FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

2019-04-22 09:28:24 | Akorn Receives 2 Generic Nose Spray Approvals

2019-04-19 18:00:00 | 3-Day Deadline Notice: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-19 17:36:17 | Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI

2019-04-18 17:00:00 | Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%

2019-04-18 16:05:00 | Akorn Receives FDA Approval for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray OTC

2019-04-18 13:47:30 | APRIL 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. – AKRX

2019-04-18 13:40:00 | 4-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Akorn, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-18 11:51:56 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX

2019-04-18 10:57:00 | AKRX, HIIQ & AMRN - Class Action Deadline Bronstein, Gewirtz & Grossman, LLC

2019-04-17 20:41:10 | Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.

2019-04-16 16:45:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akorn, Inc. of Class Action Lawsuit and Upcoming Deadline – AKRX